FAPI PET Scan for Heart Failure
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new imaging technique called 68Ga-FAPI PET to evaluate its effectiveness for individuals with heart failure with preserved ejection fraction (HFpEF), a condition where the heart pumps normally but struggles to fill with blood. The study includes three groups: individuals with HFpEF and obesity, those with active cardiac sarcoidosis (a type of inflammatory heart disease), and healthy individuals for comparison. Potential participants include those recently diagnosed with HFpEF and a BMI of 30 or more, or those with a confirmed diagnosis of cardiac sarcoidosis. Participants should not have major chronic diseases or be on specific medications. As a Phase 2 trial, this research measures the imaging technique's effectiveness in an initial, smaller group, allowing participants to contribute to significant advancements in heart disease diagnostics.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are in the Healthy Controls group, you should not be taking certain medications regularly, like anticoagulants or antihypertensives. If you are in the HFpEF or Cardiac Sarcoid groups, the protocol does not clearly state any medication restrictions.
What prior data suggests that the 68Ga-FAPI PET scan is safe for heart failure patients?
Research has shown that 68Ga-FAPI is generally safe for people. In studies, this treatment has helped visualize certain heart conditions. Although limited information exists on side effects for heart failure with preserved ejection fraction (HFpEF), earlier research has not identified major safety problems. As this trial is in an early stage, researchers are carefully monitoring the treatment for safety. Participants in this trial will be closely observed for any side effects.12345
Why are researchers excited about this trial?
The FAPI PET Scan for Heart Failure is unique because it uses a novel imaging agent, 68Ga-FAPI, to provide clearer insights into heart conditions, particularly heart failure with preserved ejection fraction (HFpEF) and cardiac sarcoidosis. Traditional heart failure treatments like beta-blockers and ACE inhibitors focus on managing symptoms and improving heart function, but they don't offer precise imaging of heart tissue. 68Ga-FAPI targets fibroblast activation protein, which is abundant in diseased heart areas, allowing for more detailed and accurate imaging of heart abnormalities. Researchers are excited about this approach because it could lead to better diagnosis and monitoring, potentially improving treatment strategies and outcomes for patients with heart conditions.
What evidence suggests that the 68Ga-FAPI PET scan is effective for heart failure?
Research has shown that the 68Ga-FAPI PET scan, which participants in this trial will undergo, might be useful for spotting early heart problems, particularly heart failure with preserved ejection fraction (HFpEF). Studies have found that this scan can detect early signs of fibrosis, a type of scarring in heart tissue associated with heart disease. This capability could help doctors identify heart issues before serious symptoms develop. One study suggested that 68Ga-FAPI PET scans can predict changes in heart function, making it a potential tool for early diagnosis and treatment planning. While more research is needed, these findings indicate that 68Ga-FAPI could play an important role in managing heart failure.26789
Who Is on the Research Team?
Gregorio Tersalvi, M.D
Principal Investigator
Mayo Clinic
Omar Abou Ezzeddine, M.D, M.S
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for patients over 30 years old with heart failure and preserved ejection fraction (HFpEF), experiencing shortness of breath during exertion. They must not have severe anemia, liver or kidney disease, active cancer, inflammatory/autoimmune diseases, a high BMI (≥30), or recent hospitalization.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo baseline PET scans to assess 68Ga-FAPI uptake
Follow-up
Participants are monitored for changes in 68Ga-FAPI uptake over time
What Are the Treatments Tested in This Trial?
Interventions
- 68Ga-FAPI
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor